Imaging oncogene expression

European Journal of Radiology

Volumn 70, Issue 2, 2009, Pages 265-273

  Mukherjee, Archana ^a   Wickstrom, Eric ^a   Thakur, Mathew L ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Antisense; Imaging; Peptide nucleic acid (PNA); Peptide PNA conjugates; Positron emission tomography (PET)

Indexed keywords

ANTISENSE; GENETIC ANALYSIS; HYBRIDIZATION PROBES; IMAGING; IMAGING AGENTS; IN-VIVO IMAGING; MOLECULAR IMAGING; PEPTIDE NUCLEIC ACID (PNA);

AMINES; GENE EXPRESSION; NUCLEIC ACIDS; POSITRON ANNIHILATION SPECTROSCOPY; POSITRONS;

POSITRON EMISSION TOMOGRAPHY;

ANTISENSE OLIGONUCLEOTIDE; FLUORINE 18; GALLIUM 68; MESSENGER RNA; PENTETIC ACID; PHOSPHORUS 32; PROTEIN BCL 2; RADIOISOTOPE; SULFUR 35; TECHNETIUM 99M; TRITIUM;

ARTICLE; CANCER DIAGNOSIS; CHELATION; GENE EXPRESSION; GENE IDENTIFICATION; GENE MUTATION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC ANALYSIS; GENETIC STABILITY; IN VIVO STUDY; ISOTOPE LABELING; MOLECULAR IMAGING; NUCLEIC ACID PROBE; ONCOGENE; ONCOGENE K RAS; ONCOGENE NEU; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOACTIVITY; RADIOGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TISSUE DISTRIBUTION; TUMOR SUPPRESSOR GENE;

ANIMALS; GENE EXPRESSION PROFILING; HUMANS; MOLECULAR PROBE TECHNIQUES; NEOPLASM PROTEINS; NEOPLASMS; ONCOGENES; POSITRON-EMISSION TOMOGRAPHY; RADIOISOTOPES; TUMOR MARKERS, BIOLOGICAL;

EID: 67349263049     PISSN: 0720048X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejrad.2009.01.043     Document Type: Article

References (73)

1. Weissleder R., and Mahmood U. Molecular imaging. Radiology 219 (2001) 316-333
2. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
3. Weinberg R.A. How cancer arises. Sci Am (1996) 62-70
4. Mankoff D.A., Link J.M., Linden H.M., Sundararajan L., and Krohn K.A. Tumor receptor imaging. J Nucl Med 49 (2008) 149S-163S
5. Plathow C., and Weber W.A. Tumor cell metabolism imaging. J Nucl Med 49 (2008) 43S-63S
6. Krohn K.A., Link J.M., and Mason R.P. Molecular imaging of hypoxia. J Nucl Med 49 (2008) 129S-148S
7. Gleave M.E., and Monia B.P. Antisense therapy for cancer. Nat Rev Cancer 5 (2005) 468-479
8. Tian X, Chakrabarti A, Amirkhanov N, et al. External imaging of CCND1, MYC and KRAS oncogene mRNAs with tumor-targeted radionuclide-PNA-peptide chimeras. In: El-Deiry W, editor. Ann NY Acad Sci 2005; 1059:106-44.
9. Mardirossian G., Lei K., Rusckowski M., et al. In vivo hybridization of technetium-99m-labeled peptide nucleic acid (PNA). J Nucl Med 38 (1997) 907-913
10. Dewanjee M.K., Haider N., and Narula J. Imaging with antisense oligonucleotides for the detection of intracellular messenger RNA and cardiovascular disease. J Nucl Cardiol 6 (1999) 345-356
11. Hnatowich D.J. Antisense and nuclear medicine. J Nucl Med 40 (1999) 693-703
12. Pickeral O.K., Li J.Z., Barrow I., Boguski M.S., Makalowski W., and Zhang J. Classical oncogenes and tumor suppressor genes: a Comparative genomics perspective. Neoplasia 2 3 (2000) 280-286
13. Revillion F., Bonneterre J., and Peyrat J.P. ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer 34 6 (1998) 791-808
14. D'Incalci M. Correlation of ErbB2 gene status, mRNA and protein expression. Onkologie 29 (2006) 246-247
15. Vaughn J.P., Iglehart J.D., Demirdji S., et al. Antisense DNA down regulation of the ERBB2 oncogene measured by a flow cytometric assay. Proc Natl Acad Sci USA 92 (1995) 8338-8342
16. Bos J.L. Ras oncogenes in human cancer: a review. Cancer Res 49 (1989) 4682-4689 [published erratum appears in Cancer Res 1990; February 15; 50(4): 1352]
17. Lowy D.R., and Willumsen B.M. Function and regulation of ras. Annu Rev Biochem 62 (1993) 851-891
18. Pellagata N.S., Sessa F., Renault B., et al. K-ras and p53 gene mutations in pancreatic cancer: Ductal and Nonductal tumors progress through different genetic lesions. Cancer Res 54 (1994) 1556-1560
19. Evans D.B., Abbruzzese J.L., and Willett C.G. Cancer of pancreas. In: Devita V.T., Hellman S., and Rosenberg S.A. (Eds). Cancer: principles and practice of Oncology (2001), Lippincott, Williams and Wilkins, Philadelphia 1126-1161
20. Berns Els M.J.J., Klijn J.G.M., van Staveren I.L., Portengen H., and Foekens J.A. c-myc amplification is a better prognostic factor than Her2/neu amplification in primary breast cancer. Cancer Res 52 (1992) 1107-1113
21. Wickstrom E.L., Bacon T.A., Gonzalez A., Freeman D.L., Lyman G.H., and Wickstrom E. Human promyelocytic leukemia HL-60 cell proliferation and c-Myc protein expression are inhibited by an antisense pentadecadeoxynucleotide targeted against c-MYC mRNA. Proc Natl Acad Sci USA 85 4 (1988) 1028-1032
22. Weinstat-Saslow D., Merino M.J., Manrow R.E., et al. Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions. Nat Med 1 (1995) 1257-1260
23. Hermine O., Haioun C., Lepage E., et al. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkins lymphoma. Blood 87 (1996) 265-272
24. Pepper C., Bentley P., and Hoy T. Regulation of clinical chemo resistance by bcl-2 and bax oncoproteins in B-cell chronic lymphocytic leukemia. Br J Haematol 95 (1996) 513-517
25. Croce C.M. Oncogenes and cancer. N Engl J Med 358 (2008) 502-511
26. Hollstein M., Sidransky D., Vogelstein B., and Harris C.C. p53 mutations in human cancers. Science 253 (1991) 49-53
27. Sauter E.R., Herlyn M., Liu S.C., Litwin S., and Ridge J.A. Prolonged response to antisense cyclin D1 in a human squamous cancer xenograft model. Clin Cancer Res 6 (2000) 654-660
28. Wickstrom E., Bacon T.A., and Wickstrom E.L. Down regulation of c-MYC antigen expression in lymphocytes of Eμ-c-myc transgenic mice treated with anti-c-myc DNA methylphosphonates. Cancer Res 52 (1992) 6741-6745
29. Wickstrom E. Clinical trials of genetic therapy with antisense DNA and DNA vectors (1998), Marcel Dekker, New York
30. Webb A., Cunningham D., Cotter F., et al. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 349 (1997) 1137-1141
31. Bayever E., Haines K.M., Iversen P.L., et al. Selective cytotoxicity to human leukemic myoblasts produced by oligodeoxyribonucleotide phosphorothioates complementary to p53 nucleotide sequences. Leuk Lymphoma 12 (1994) 223-226
32. Paroo Z., and Corey D.R. Imaging gene expression using oligonucleotides and peptide nucleic acids. J Cell Biochem 90 (2003) 437-442
33. Swayze E.E., and Balkrishen B. The medicinal chemistry of oligonucleotides. In: Crooke S.T. (Ed). Antisense drug technology: principles, strategies and applications (2008), CRC press, USA 144-172
34. Zendegui J.G., Vazquez K.M., Tindley J.H., et al. In vivo stability and kinetics of absorption and disposition of 3′ phosphopropyl amine oligonucleotides. Nucleic Acids Res 20 2 (1992) 307-314
35. Thakur M.L., Tian X., Amirkhanov N., et al. The role of radiolabeled peptide nucleic acid chimeras and peptides in imaging oncogene expression. Indian J Nucl Med 19 3 (2004) 98-114
36. Lebedev A.V., and Wickstrom E. The chirality problem in P-substituted oligonucleotides. In: Trainor G. (Ed). Perspectives in drug discovery and design (1996), ESCOM Science Publishers, Leiden 17-40
37. Monia B.P., Lesnik E.A., Gonzalez C., et al. Evaluation of 2′ modified oligonucleotides containing 2′-deoxy gaps as antisense inhibitors of gene expression. J Biol Chem 268 (1993) 14514-14522
38. Bacon T.A., Morvan F., Rayner B., et al. Alpha-oligodeoxynucleotide stability in serum, subcellular extracts and culture media. J Biochem Biophys Methods 16 4 (1988) 311-318
39. Ho P.T., Ishiguro K., Wickstrom E., et al. Non-sequence-specific inhibition of transferin receptor expression in HL-60 leukemia cells by phosphorothioate oligodeoxynucleotides. Antisense Res Dev 1 4 (1991) 329-342
40. Cook D. Antisense medicinal chemistry. In: Crooke S.T. (Ed). Antisense research and applications (1998), Springer-Verlag, Berlin-Heidelberg 51-92
41. Good L., and Nielsen P.E. Progress in developing PNA as a gene targeted drug. Antisense Nucleic Acid Drug Dev 7 4 (1997) 431-437
42. Tian X., and Wickstrom E. Continuous solid phase synthesis and disulfide cyclization of peptide-PNA-peptide chimeras. Org Lett 4 (2002) 4013-4016
43. Nielsen P.E. Antisense properties of peptide nucleic acids. In: Crooke S.T. (Ed). Antisense research and applications (1998), Springer-Verlag, Berlin-Heidelberg 545-557
44. Agrawal S. Antisense oligonucleotides: towards clinical trials. Trends Biotechnol 14 10 (1996) 376-387
45. Olivier S., and Bolard J. Delivery agents for oligonucleotides. In: Sioud M. (Ed). Methods in molecular biology, vol. 252, ribozymes and siRNA protocols (2004), Totowa, New Jersey, Humana Press 545-568
46. Sato N., Kobayashi H., Saga T., et al. Tumor targeting and imaging of intraperitoneal tumors by use of antisense oligo-DNA complexed with dendrimers and/or avidin in mice. Clin Cancer Res 7 (2001) 3606-3612
47. Gray G.D., Basu S., and Wickstrom E. Transformed and immortalized cellular uptake of oligodeoxynucleoside phosphorothioates, 3′Alkylamino oligodeoxynucleosides, 2′-O-methyl oligoribonucleotides, Oligodeoxynucleosides methyl phosphonates, and peptide nucleic acids. Biochem Pharmacol 53 (1997) 1465-1476
48. Tavitian B., Terrazzino S., Kuhnast B., et al. In vivo imaging of oligonucleotides with positron emission tomography. Nat Med 4 4 (1998) 467-471
49. Basu S., and Wickstrom E. Synthesis and characterization of a peptide nucleic acid conjugated to a d-peptide analog of insulin like growth factor1 for increased cellular uptake. Bioconj Chem 8 (1997) 481-488
50. 111In-labeled PNA-peptide conjugates. J Nucl Med 49 (2008) 430-438
51. Boffa L.C., Scarfi S., Mariani M.R., et al. Dihydrotestosterone as a selective cellular/nuclear localization vector for anti-Gene peptide nucleic acid in prostratic carcinoma cells. Cancer Res 60 (2000) 2258-2262
52. Sun X., Fang H., Li X., et al. MicroPET imaging of MCF-7 tumors in mice via unr mRNA targeted peptide nucleic acids. Bioconj Chem 16 (2005) 294-305
53. Lewis M.R., Jia F., Gallazzi F., et al. Radiometal-labeled peptide-PNA conjugates for targeting bcl-2 expression: Preparation, characterization and in vitro mRNA binding. Bioconj Chem 13 (2002) 1176-1180
54. Hnatowich D.J., Winnard P., Virzi F., et al. Technetium-99m labeling of DNA oligonucleotides. J Nucl Med 36 (1995) 2306-2314
55. Dewanjee M.K., Ghafouripour A.K., Kapadvanjwala M., et al. Noninvasive imaging of c-myc oncogene messenger RNA with indium-111-antisense probes in a mammary tumor bearing mouse model. J Nucl Med 35 (1994) 1054-1063
56. 99mTc-peptide nucleic acid probes for imaging oncogene mRNAs in tumors. Nucl Med Commun 24 8 (2003) 857-863
57. Dewanjee M.K., Ghafouripour A.K., Werner R.K., Serafini A.N., and Sfakianakis G.N. Development of sensitive radioiodinated antisense oligonucleotide probes by conjugation technique. Bioconj Chem 2 (1991) 195-200
58. 64Cu. J Inorg Biochem 98 (2004) 1874-1901
59. 68Ga-labeled oligonucleotides for in vivo imaging with PET. J Nucl Med 45 (2004) 347-355
60. 64Cu] DO3A-PNA-IGF1 analog radiohybridization probe. J Nucl Med 48 10 (2007) 1699-1707
61. Tian X., Chakrabarti A., Amirkhanov N., et al. Receptor mediated internalization of chelator-PNA-peptide hybridization probes for radioimaging or magnetic resonance imaging of oncogene mRNAs in tumors. Biochem Soc Trans 35 (2007) 72-76
62. n-polydiamidopropanoyl-peptide nucleic acid-d (Cys-Ser-Lys-Cys) magnetic resonance contrast agents. Biopolymers 89 (2008) 1061-1076
63. Tavitian B. In vivo imaging with oligonucleotides for diagnosis and drug development. Gut 52 (2003) 40-47
64. 68Ga-labelled phosphodiester, phosphorothioate and 2′-O-methyl phosphodiester oligonucleotides in normal rats. Eur J Pharm Sci 26 1 (2005) 26-38
65. 68Ga-labelled oligonucleotides for in vivo imaging with PET. J Nucl Med 45 (2004) 347-355
66. WAF-1/CIP-1 gene expression in MDA-MB-468 human breast cancer xenografts. Eur J Nucl Med 30 (2003) 1273-1280
67. Urbain J.L.C., Shore S.K., Vekemans M.C., et al. Scintigraphic imaging of oncogenes with antisense probes: does it make sense?. Eur J Nucl Med 22 (1995) 499-504
68. Stalteri M.A., and Mather S.J. Hybridization and cell uptake studies with radiolabeled antisense oligonucleotides. Nucl Med Commun 22 11 (2001) 1171-1179
69. Cammilleri S., Sangrajrang S., Perdereau B., et al. Biodistribution of iodine-125 tyramine transforming growth factor α antisense oligonucleotide in athymic mice with a human mammary tumour xenograft following intratumoral injection. Eur J Nucl Med 23 (1996) 448-452
70. Wickstrom E., Thakur M.L., and Sauter E.R. Radiolabeled peptide nucleic acid oncogene probes conjugated to receptor-specific peptide analogs. In: Janson C.G., and During M.J. (Eds). Peptide nucleic acids, morpholinos, and related antisense biomolecules (2006), Landes Bioscience/Kluwer Academic/Plenum Publishers, New York 59-86
71. 99mTc] peptide-PNA-peptide chimeras. J Nucl Med 45 12 (2004) 2070-2082
72. 99mTc] peptide-peptide nucleic acid-peptide chimera. Bioconj Chem 16 (2005) 70-79
73. 64Cu] DO3A-peptide nucleic acid-peptide nanoparticles. Cancer Biol Ther 6 6 (2007) 948-956